FDA authorizes new combination treatment for specific metastatic prostate cancer.

AI-generated NewsSnap summary based on source reporting.
Published: 2026-06-12
Category: health
Source: Oncology Nursing News
Original source

The FDA has approved capivasertib in conjunction with abiraterone and prednisone for certain prostate cancer patients. This treatment targets adults with PTEN-deficient metastatic androgen pathway modulation–naive or sensitive prostate cancer. The approval follows positive results from the CAPItello-281 trial.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai